103 related articles for article (PubMed ID: 20218811)
1. Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines.
Civallero M; Cosenza M; Grisendi G; Marcheselli L; Todoerti K; Sacchi S
Leuk Lymphoma; 2010 Apr; 51(4):671-9. PubMed ID: 20218811
[TBL] [Abstract][Full Text] [Related]
2. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway.
Querfeld C; Rizvi MA; Kuzel TM; Guitart J; Rademaker A; Sabharwal SS; Krett NL; Rosen ST
J Invest Dermatol; 2006 Jul; 126(7):1641-7. PubMed ID: 16645590
[TBL] [Abstract][Full Text] [Related]
3. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells.
Lee KW; Kim SG; Kim HP; Kwon E; You J; Choi HJ; Park JH; Kang BC; Im SA; Kim TY; Kim WH; Bang YJ
Cancer Res; 2008 Mar; 68(6):1916-26. PubMed ID: 18339873
[TBL] [Abstract][Full Text] [Related]
4. Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines.
Cosenza M; Civallero M; Grisendi G; Marcheselli L; Roat E; Bari A; Sacchi S
Ann Hematol; 2012 Oct; 91(10):1613-22. PubMed ID: 22623160
[TBL] [Abstract][Full Text] [Related]
5. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
Rizvi MA; Ghias K; Davies KM; Ma C; Weinberg F; Munshi HG; Krett NL; Rosen ST
Mol Cancer Ther; 2006 Jul; 5(7):1783-9. PubMed ID: 16891464
[TBL] [Abstract][Full Text] [Related]
6. Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells.
Ruvolo PP; Zhou L; Watt JC; Ruvolo VR; Burks JK; Jiffar T; Kornblau S; Konopleva M; Andreeff M
J Cell Biochem; 2011 Jun; 112(6):1696-707. PubMed ID: 21360576
[TBL] [Abstract][Full Text] [Related]
7. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
Neri A; Marmiroli S; Tassone P; Lombardi L; Nobili L; Verdelli D; Civallero M; Cosenza M; Bertacchini J; Federico M; De Pol A; Deliliers GL; Sacchi S
Leuk Lymphoma; 2008 Jul; 49(7):1374-83. PubMed ID: 18452078
[TBL] [Abstract][Full Text] [Related]
8. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
Graff JR; McNulty AM; Hanna KR; Konicek BW; Lynch RL; Bailey SN; Banks C; Capen A; Goode R; Lewis JE; Sams L; Huss KL; Campbell RM; Iversen PW; Neubauer BL; Brown TJ; Musib L; Geeganage S; Thornton D
Cancer Res; 2005 Aug; 65(16):7462-9. PubMed ID: 16103100
[TBL] [Abstract][Full Text] [Related]
9. The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
Cosenza M; Civallero M; Pozzi S; Marcheselli L; Bari A; Sacchi S
Hematol Oncol; 2015 Dec; 33(4):166-75. PubMed ID: 25394177
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Moreau AS; Jia X; Ngo HT; Leleu X; O'Sullivan G; Alsayed Y; Leontovich A; Podar K; Kutok J; Daley J; Lazo-Kallanian S; Hatjiharissi E; Raab MS; Xu L; Treon SP; Hideshima T; Anderson KC; Ghobrial IM
Blood; 2007 Jun; 109(11):4964-72. PubMed ID: 17284528
[TBL] [Abstract][Full Text] [Related]
11. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.
Jian W; Yamashita H; Levitt JM; Lerner SP; Sonpavde G
Mol Cancer Ther; 2009 Jul; 8(7):1772-8. PubMed ID: 19509273
[TBL] [Abstract][Full Text] [Related]
12. The serine-threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells.
Kheirallah S; Fruchon S; Ysebaert L; Blanc A; Capilla F; Marrot A; Alsaati T; Frenois FX; Benhadji KA; Fournié JJ; Laurent G; Bezombes C
Br J Pharmacol; 2013 Dec; 170(7):1374-83. PubMed ID: 23992368
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer.
Lee SH; Chen T; Zhou J; Hofmann J; Bepler G
Clin Lung Cancer; 2010 May; 11(3):169-75. PubMed ID: 20439192
[TBL] [Abstract][Full Text] [Related]
14. The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells.
Jane EP; Pollack IF
Cancer Lett; 2008 Sep; 268(1):46-55. PubMed ID: 18462865
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Green LJ; Marder P; Ray C; Cook CA; Jaken S; Musib LC; Herbst RS; Carducci M; Britten CD; Basche M; Eckhardt SG; Thornton D
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3408-15. PubMed ID: 16740765
[TBL] [Abstract][Full Text] [Related]
16. Enzastaurin.
Chen YB; LaCasce AS
Expert Opin Investig Drugs; 2008 Jun; 17(6):939-44. PubMed ID: 18491994
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.
Serova M; Astorgues-Xerri L; Bieche I; Albert S; Vidaud M; Benhadji KA; Emami S; Vidaud D; Hammel P; Theou-Anton N; Gespach C; Faivre S; Raymond E
Mol Cancer Ther; 2010 May; 9(5):1308-17. PubMed ID: 20406951
[TBL] [Abstract][Full Text] [Related]
18. Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors.
Molè D; Gagliano T; Gentilin E; Tagliati F; Pasquali C; Ambrosio MR; Pansini G; Degli Uberti EC; Zatelli MC
Endocr Relat Cancer; 2011 Aug; 18(4):439-50. PubMed ID: 21606156
[TBL] [Abstract][Full Text] [Related]
19. Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells.
Morgillo F; Martinelli E; Troiani T; Laus G; Pepe S; Gridelli C; Ciardiello F
Mol Cancer Ther; 2008 Jun; 7(6):1698-707. PubMed ID: 18566241
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Vogl UM; Berger W; Micksche M; Pirker C; Lamm W; Pichelmeyer O; Zielinski CC; Schmidinger M
Cancer Lett; 2009 May; 277(2):218-26. PubMed ID: 19171421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
